This is a working overview of GRF(1-29), written for readers who want more than a one-paragraph summary but less than a textbook.
Reviewed 2026-01-28. Anything still debated is marked as such rather than presented as settled.
CJC-1295 is a synthetic peptide modeled on growth hormone-releasing hormone, the hypothalamic signal that prompts the pituitary to release growth hormone. Its sequence corresponds to the first twenty-nine residues of human GHRH, with four substitutions that slow enzymatic breakdown. Early descriptions placed the compound in research on growth hormone deficiency and related conditions, and later literature groups it with the long-acting GHRH analogs. The name appears in both laboratory and popular fitness writing, where it sometimes labels chemically different peptides.
Two related peptides circulate under the CJC-1295 label, and they differ mainly in how long they persist in circulation. The version carrying a drug affinity complex includes a maleimidopropionic acid linker that forms a covalent bond with serum albumin. The other version, usually written as modified GRF(1-29) or tetrasubstituted GRF(1-29), lacks that linker and is cleared quickly. Mixing the two produces inconsistent readings of published half-life values, because the linker rather than the receptor-facing sequence drives most of the difference.
Two principal forms appear in the literature and in research supply. One carries a drug affinity complex, a maleimide-based group that forms a covalent bond with circulating albumin. This linkage slows clearance and produces a long-lasting elevation of peptide levels. The other form lacks that group and is often labeled MOD GRF(1-29). It has a much shorter circulation time. Both variants retain the same core receptor-binding sequence. Reported half-lives differ substantially between the two.
At the pituitary, the peptide binds the growth hormone-releasing hormone receptor on somatotroph cells. Receptor activation raises intracellular cyclic AMP and triggers release of stored growth hormone. Somatostatin and other hypothalamic signals modulate this response. Negative feedback from insulin-like growth factor 1 also influences output. The same regulatory architecture operates with the native hormone. Whether the synthetic analog alters feedback dynamics over repeated exposure remains an open question. Most published receptor work uses cell models rather than intact human systems.
CJC-1295 is a synthetic peptide belonging to the growth hormone-releasing hormone analog family. It comprises twenty-nine amino acid residues derived from the N-terminal region of natural GHRH. The molecule incorporates several non-natural substitutions that increase resistance to enzymatic degradation. These modifications extend its activity compared with the native hormone fragment. Researchers use it to study pituitary growth hormone secretion in laboratory and clinical settings. This compound is distinct from native GHRH in its stability profile.
| Property | Value | Notes |
|---|---|---|
| Class | Synthetic peptide | GHRH receptor agonist |
| Sequence length | 29 amino acids | Derived from human GHRH |
| Molecular weight | About 3368 Da without linker | Albumin-binding form is heavier |
| Appearance | White to off-white lyophilized powder | Common form for research reference material |
| Typical storage | -20 °C or below, desiccated | Protect powder from light and moisture |
CJC-1295 is the name used for a synthetic peptide modeled on growth hormone-releasing hormone, the hypothalamic signal that prompts the pituitary to release growth hormone. The compound was described by a Canadian drug discovery company in the mid-2000s as a long-acting research tool. Two closely related molecules share the name in practice: one carries a drug affinity complex, or DAC, group, and one does not. The distinction matters because the two behave differently in circulation.
The peptide backbone corresponds to GRF(1-29), the first 29 residues of native growth hormone-releasing hormone, which retains most of the receptor-activating activity of the full-length molecule. Four substitutions distinguish the analog from the natural sequence: D-alanine at position 2, glutamine at position 8, alanine at position 15, and leucine at position 27. These changes slow cleavage by dipeptidyl peptidase IV, the enzyme that degrades native hormone in plasma within minutes. The outcome is improved enzymatic stability combined with a still brief residence time when no additional modification is present.
Naming in this area is inconsistent, and readers should treat product labels with care. In much of the literature and in vendor catalogs, the unqualified term refers to the albumin-binding version, while the version lacking the DAC group appears as modified GRF(1-29), mod GRF(1-29), or the same name with a without-DAC qualifier. Because one abbreviation has been applied to both materials, the only reliable way to identify a sample is to check the stated sequence and the presence of the linker.
Two related forms circulate in technical discussion under the same family name. The original version carries a drug affinity complex (DAC) that binds covalently to serum albumin after administration, and this linkage substantially extends circulation time. A second form, frequently written as modified GRF(1-29) or CJC-1295 without DAC, lacks that linker and clears much faster. The naming is a frequent source of confusion because the shorthand CJC-1295 can refer to either form depending on the source. Reports sometimes fail to specify which variant was studied.
The peptide backbone includes a D-alanine at position two, which resists cleavage by dipeptidyl peptidase IV, and several other substitutions that reduce degradation. Its molecular weight is roughly 3.4 kDa without the linker and about 3.6 kDa with it. The molecule is water soluble and is normally supplied as a lyophilized powder. Precise sequence and mass values depend on which variant is described, so technical documents usually state the exact form being referenced.
CJC-1295 is a synthetic peptide designed as a long-acting analogue of growth hormone-releasing hormone (GHRH). Its structure derives from the first 29 amino acids of native GHRH, a fragment often called GRF(1-29). Four substitutions were introduced to slow enzymatic breakdown and extend activity relative to the natural sequence. The compound was developed by ConjuChem as part of a broader effort to improve the pharmacokinetic profile of peptide hormones. It is studied in laboratory and clinical research settings rather than appearing as a naturally occurring substance.
CJC-1295 is a synthetic peptide designed to mimic growth hormone-releasing hormone (GHRH), the endogenous signal that prompts the pituitary gland to release growth hormone. The compound is a modified fragment of the natural hormone, spanning the first twenty-nine amino acids of GHRH with several substitutions that slow enzymatic breakdown. Two variants circulate in research settings: one carrying a drug affinity complex (DAC) and one without it. The DAC-free form is frequently labelled Mod GRF(1-29) in catalogs and discussion forums.
The peptide binds GHRH receptors on somatotroph cells within the anterior pituitary, triggering a signalling cascade that increases growth hormone secretion. Its improved resistance to dipeptidyl peptidase IV degradation distinguishes it from the parent hormone. In the DAC-bearing version, a maleimide group reacts with a cysteine residue on serum albumin, forming a covalent bond that keeps the peptide in circulation far longer. That albumin attachment is the central design feature separating the two research variants.
Pharmacokinetic behaviour differs sharply between the two forms. The DAC-bearing peptide shows an extended circulation time measured in days, whereas the version without the complex is cleared within roughly half an hour. This gap shapes how researchers design dosing schedules in animal models. Whether the prolonged presence of the DAC form produces effects meaningfully different from the short-acting variant remains an open question, since comparative human data are scarce.
Once in circulation, the peptide binds the growth hormone-releasing hormone receptor displayed on pituitary somatotroph cells. Receptor activation couples to Gs proteins, elevates intracellular cyclic AMP, and drives protein kinase A signaling inside the cell. That cascade increases discharge of growth hormone into the bloodstream. The analog therefore operates through a receptor pathway that already exists for the body's own releasing hormone, rather than through an engineered artificial target.
Clearance profiles diverge sharply between the two versions. The albumin-binding molecule stays in plasma for several days, whereas the unmodified analog is largely gone within about half an hour in reported work. Cleavage by dipeptidyl peptidase IV is a major contributor to the short life of the unmodified sequence. These gaps mean the two versions cannot be substituted for each other in study design or in reading results side by side.
Reports on this compound commonly follow serum growth hormone and insulin-like growth factor 1 across defined time windows. Protocols differ in sampling frequency, assay platform, and participant characteristics, which makes direct comparison between publications difficult. Some work focuses on pulsatile release patterns instead of average concentrations. Whether repeated exposure alters endogenous hormone rhythms over long periods remains an open question, and the formal literature is thinner than the volume of informal commentary implies.
Kenneth D. Tew is a Scottish-American pharmacologist, academic and author. He is a professor in the Department of Cell & Molecular Pharmacology and the John C. West Endowed Chair in Cancer Research at the Medical University of South Carolina. Tew's research primarily focuses on identifying cancer strategies with strong translational potential, particularly in the context of redox pathways, and resistance to various drugs to understand redox mechanisms and their connections to essential signaling pathways. He has authored, co-authored and edited research articles and books such as Preclinical and Clinical Modulation of Anticancer Drugs and Basic Science of Cancer. He is the recipient of the Outstanding Investigator Grant from the National Cancer Institute in 1993, the 2003 American Cancer Society Scientific Research Award and the 2010 Astellas USA Foundation Award from the American Society for Pharmacology and Experimental Therapeutics. Tew is an Elected Fellow of the American Association for the Advancement of Science and the American Society for Pharmacology and Experimental Therapeutics. He is an Executive Editor of Biomedicine & Pharmacotherapy.
Each nucleotide in RNA contains a ribose sugar, with carbons numbered 1' through 5'. A base is attached to the 1' position, in general, adenine (A), cytosine (C), guanine (G), or uracil (U). Adenine and guanine are purines, and cytosine and uracil are pyrimidines. A phosphate group is attached to the 3' position of one ribose and the 5' position of the next. The phosphate groups have a negative charge each, making RNA a charged molecule (polyanion). The bases form standard hydrogen bonds between cytosine and guanine and between adenine and uracil, while guanine and uracil can pair through a non-canonical G–U wobble base pair. However, other interactions are possible, such as a group of adenine bases binding to each other in a bulge, or the GNRA tetraloop that has a guanine–adenine base-pair.
=== Elections === In 1988, incumbent Republican congressman Jim Jeffords decided to run for the U.S. Senate, vacating the House seat representing Vermont's at-large congressional district. Former lieutenant governor Peter P. Smith won the House election with a plurality, securing 41% of the vote. Sanders, who ran as an independent, placed second with 38% of the vote, while Democratic state representative Paul N. Poirier placed third with 19%. Two years later, he ran for the seat again and defeated Smith by a margin of 56% to 39%. Sanders was the first independent elected to the U.S. House of Representatives since Frazier Reams of Ohio won his second term in 1952, as well as the first socialist elected to the House since Vito Marcantonio, from the American Labor Party, who won his last term in 1948. Sanders was a representative from 1991 until he became a senator in 2007, winning reelection by large margins except during the 1994 Republican Revolution, when he won by 3%, with 50% of the vote.
==== Radioactive detection ==== Radioactive labels do not require enzyme substrates, but rather, allow the placement of medical X-ray film directly against the Western blot, which develops as it is exposed to the label and creates dark regions which correspond to the protein bands of interest (see image above). The importance of radioactive detections methods is declining due to its hazardous radiation , because it is very expensive, health and safety risks are high, and ECL (enhanced chemiluminescence) provides a useful alternative.
Sources: en.wikipedia.org
=== Recurring or guest === Avantika Vandanapu as Ophelia, a young advanced witch Madelaine Petsch as Kira, Ben's girlfriend Elle Chapman as Ashley, one of Kira's friends Berto Colón as Joe the Doorman Fedor Steer as Mr. Nas, an elderly gentleman being cared for by Constance and Ben John Waters as Mr. Phibes, a mysterious phlebotomist John Carroll Lynch as Twisty the Clown, a disgraced clown and a serial killer, reprising his role from Freak Show and Cult Tig Notaro as Ricochet, a clown school teacher Jamie Brewer as: Adelaide Langdon, Constance's daughter, reprising her role from Murder House Nan, a witch, reprising her role from Coven and Apocalypse Mena Suvari as Elizabeth Short, a ghost of an aspiring actress, reprising her role from Murder House and Apocalypse Paul Anthony Kelly as young Nas Mat Fraser as Paul the Illustrated Seal, a freak show member with phocomelia, reprising his role from Freak Show Orlando Jones as Papa Legba, a gatekeeper of the spirit world; Jones replaces Lance Reddick, who portrayed Papa Legba in Coven and Apocalypse Seth Gabel as Jeffrey Dahmer, a serial killer, reprising his role from Hotel Zach Villa as Richard Ramirez, a serial killer, reprising his role from 1984 Alex Consani as Morwenna Grace Dumdaw Cara Delevingne Charlie Carver
Birch bark tar use as an adhesive began in the Middle Paleolithic. Neanderthals produced tar through dry distillation of birch bark as early as 200,000 years ago. A 2019 study demonstrated that birch bark tar production can be a simpler, more discoverable process by directly burning birch bark under overhanging stone surfaces in open-air conditions. However, at Königsaue (Germany), Neanderthals did not make tar with this method but rather employed a technically more demanding underground production method. A find from the Dutch North Sea and two tools from the Italian site Campitello show that Neanderthals used birch bark tar as a backing on small 'domestic' stone tools. Birch bark tar also has been used as a disinfectant, in leather dressing, and in medicine. A piece of 5,000-year-old chewing gum made from birch bark tar, and still bearing tooth imprints, was found in Kierikki, Finland. Genetic material left in the gum enabled novel research to identify population movements, types of food consumed, and types of oral bacteria found on their teeth. A different chewing gum sample, dated to 5,700 years old, was found in southern Denmark. A complete human genome and oral microbiome was sequenced from chewed birch bark tar. Researchers identified that the individual who chewed the gum was a female who was closely related genetically to hunter-gatherers from mainland Europe. Fletching on arrows were fastened with birch bark tar, and rawhide lashing and birch bark tar were used to fix axe blades in the Mesolithic period.
== Judiciary == Hima Kohli (born 1959), Judge of the Supreme Court of India and former Chief Justice of the Telangana High Court Nalin Kohli, Indian advocate and politician Permod Kohli (born 1951), Indian Judge and former Chief Justice of Sikkim High Court Pushpa Kumari Kohli (born 1990), first female Hindu police officer in Pakistan
Sources: en.wikipedia.org
Natural GHRH is degraded quickly by dipeptidyl peptidase-4 and related enzymes, giving it a half-life measured in minutes. CJC-1295 carries substitutions that slow that breakdown, so it stays intact longer. Both act at the same pituitary receptor and produce the same class of signal.
The label was first attached to the albumin-binding form during early development work. A shorter analog without the linker later became known by the same name in informal use. Published papers normally state which version was studied, so the methods section resolves the ambiguity.
It is a synthetic peptide rather than a steroid, and it does not occur naturally in the body. Its sequence is derived from a hypothalamic hormone called growth hormone-releasing hormone. It works as a receptor agonist rather than as a replacement for that hormone.
It is a synthetic peptide modeled on growth hormone-releasing hormone. The molecule is used in research on pituitary growth hormone secretion. It differs from the natural hormone through several stabilizing substitutions.